Treating Aspirin Resistance with GuidEd Therapy in Diabetes (TARGET-Diabetes) Study

Phase 4

Recruiting

• Conditions: aspirin resistance; type 2 diabetes; Cardiovascular - Coronary heart disease; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12611001132932
• Lead Sponsor: RMIT University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Impaired fasting glucose IFG (110 – 125 mg / dL) or;
Impaired glucose tolerance IGT (140 – 199 mg / dL) or;
Type-2 diabetes (IFG > 135 mg / dL or IGT > 200 mg / dL)

Exclusion Criteria

salicylate or thienopyridine allergy or intolerance, history of haemorrhagic stroke, aneurysm or any stroke < 3 months, any thienopyridine < 3 days, history of low platelet count, history of bleeding diathesis, clinical findings in the judgement of the investigator associated with increased risk of bleeding, oral anticoagulation or other antiplatelet therapy, history of withdrawal from study due to non-compliance with medication, any condition associated with poor treatment compliance, including alcoholism, mental illness, or drug dependence, investigative site personnel directly affiliated with the study or immediate family, presently enrolled in another drug study, women who are known to be pregnant, have given birth within the past 90 days, or are breast feeding, concomitant medical illness that in the opinion of the investigator is associated with reduced survival over the expected treatment period, known severe hepatic dysfunction, planned travel or other reason why participant might be unable to cooperate with protocol requirements during the study medication period.

Study & Design

• Study Type: Interventional
• Study Design: Not specified